The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

doi:10.1093/neuonc/noae107

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

Neuro-oncology - 3 Oct 2024

van den Bent Martin J, French Pim J, Brat Daniel, Tonn Joerg C, Touat Mehdi, Ellingson Benjamin M, Young Robert J, Pallud Johan, von Deimling Andreas, Sahm Felix, Figarella Branger Dominique, Huang Raymond Y, Weller Michael, Mellinghoff Ingo K, Cloughsey Tim F, Huse Jason T, Aldape Kenneth, Reifenberger Guido, Youssef Gilbert, Karschnia Philipp, Noushmehr Houtan, Peters Katherine B, Ducray Francois, Preusser Matthias, Wen Patrick Y

Abstract excerpt

The 2016 and 2021 World Health Organization 2021 Classification of central nervous system tumors have resulted in a major improvement in the classification of isocitrate dehydrogenase (IDH)-mutant gliomas. With more effective treatments many patients experience prolonged survival. However, treatment guidelines are often still based on information from historical series comprising both patients with IDH wild-type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Clinical Decision-Making

Share to Enzyme Inhibitors

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Neoplasm Grading

Source

Open in PubMed Open full text

Identifiers

PMID: 38912846
DOI: 10.1093/neuonc/noae107
PMCID: PMC11449017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?PMID 38912846Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.Semantic proximity Read ↗

Updates on the WHO diagnosis of IDH-mutant glioma.Semantic proximity Read ↗

Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.Semantic proximity Read ↗

Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Treatment and outcomes of IDH1-mutant gliomas in elderly patients.Semantic proximity Read ↗

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensusSemantic proximity Read ↗

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Semantic proximity Read ↗

Distinguishing IDH-mutant astrocytomas from IDH-wildtype glioblastomas using qualitative and quantitative MRI features: a WHO CNS5 study.Semantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.